CRMD

CorMedix Inc. [CRMD] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CRMD Stock Summary

Top 10 Correlated Stocks

CRMD

In the News

CRMD Financial details

Company Rating
-
Market Cap
320.1M
Income
401.56M
Revenue
29.7K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
40
Optionable
No
Shortable
Yes
Earnings
12 Mar 2024
P/E
0.51
Forward P/E
-
PEG
-0
P/S
6661.89
P/B
2.45
P/C
-
P/FCF
-5.82
Quick Ratio
11.29
Current Ratio
11.61
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
9.16
EPS next Y
-
EPS next Q
-
EPS this Y
-1.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-13.29%
Revenue last 5Y
-31.38%
Revenue Q/Q
-
EPS Q/Q
-32%
-
-
-
-
SMA20
-12.16%
SMA50
-14.15%
SMA100
-23.14%
Inst Own
-
Inst Trans
-
ROA
439%
ROE
-207%
ROC
-0.5%
Gross Margin
99%
Oper. Margin
-140321%
Profit Margin
1351973%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.57-6.8897
52W High
+12.33%
52W Low
+237%
RSI
25.26
Rel Volume
4.39
Avg Volume
501.56K
Volume
2.2M
Perf Week
-38.56%
Perf Month
-35.44%
Perf Quarter
-18.7%
Perf Half Y
-16.27%
-
-
-
-
Beta
1.847
-
-
Volatility
1.92%, 1.25%
Prev Close
0.45%
Price
6.74
Change
-5.2%

Something similar

Top by Market Cap
GOOG
JPM
1YD.DE
META
VTSAX
Same Sector
ALPHA.PA
ATT.ST
CFRX
MSRT
IMMP
Top Correlated Stocks
FTF.L
MIG1.L
CCTC
ZNWD.L
SAVA
Similar Market Cap
HBNC
DGN.L
ED4.DE
VGSCX
ACT.WA

Company Profile

Healthcare Biotechnology
  • Volume Average 501.56K
  • Market Capitalization 320.1M
  • Employee 40
  • CEO Mr. Joseph Todisco MBA
  • Headquarters Berkeley Heights,NJ,US
  • IPO Date 2010-05-13
  • Website https://www.cormedix.com

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.